Haematologica (Nov 2019)
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial
- Riccardo Bruna,
- Fabio Benedetti,
- Carola Boccomini,
- Caterina Patti,
- Anna Maria Barbui,
- Alessandro Pulsoni,
- Maurizio Musso,
- Anna Marina Liberati,
- Guido Gini,
- Claudia Castellino,
- Fausto Rossini,
- Fabio Ciceri,
- Delia Rota-Scalabrini,
- Caterina Stelitano,
- Francesco Di Raimondo,
- Alessandra Tucci,
- Liliana Devizzi,
- Valerio Zoli,
- Francesco Zallio,
- Franco Narni,
- Alessandra Dondi,
- Guido Parvis,
- Gianpietro Semenzato,
- Francesco Lanza,
- Tommasina Perrone,
- Francesco Angrilli,
- Atto Billio,
- Angela Gueli,
- Barbara Mantoan,
- Alessandro Rambaldi,
- Alessandro Massimo Gianni,
- Paolo Corradini,
- Roberto Passera,
- Marco Ladetto,
- Corrado Tarella
Affiliations
- Riccardo Bruna
- Onco-Hematology Division, IEO, European Institute of Oncology IRCCS, Milano
- Fabio Benedetti
- Hematology University Division, Verona
- Carola Boccomini
- Hematology Division, Città della Salute Hospital, Torino
- Caterina Patti
- Hematology Division, Azienda Villa Sofia-Cervello, Palermo
- Anna Maria Barbui
- Hematology Division, Papa Giovanni XXIII Hospital, Bergamo
- Alessandro Pulsoni
- Department of Cellular Biotechnologies and Hematology, La Sapienza University, Roma
- Maurizio Musso
- Hematology Unit, La Maddalena Hospital, Palermo
- Anna Marina Liberati
- SC Oncoematologia, Università degli Studi di Perugia
- Guido Gini
- Hematology University Division, Ancona
- Claudia Castellino
- Department of Hematology, S. Croce e Carle Hospital, Cuneo
- Fausto Rossini
- Hematology University Division, Monza
- Fabio Ciceri
- Hematology Unit HSR, Milano
- Delia Rota-Scalabrini
- Oncologia Medica, Cancer Institute FPO, IRCCS, Candiolo
- Caterina Stelitano
- Hematology Division, Reggio Calabria
- Francesco Di Raimondo
- Hematology Univiversity Division, Catania
- Alessandra Tucci
- Division of Hematology, Brescia
- Liliana Devizzi
- University Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Valerio Zoli
- Hematology Division, S. Camillo Hospital, Roma
- Francesco Zallio
- SC Ematologia AO SS Antonio e Biagio e Cesare Arrigo, Alessandria
- Franco Narni
- Hematology University Division, Modena
- Alessandra Dondi
- Division of Oncology, Modena
- Guido Parvis
- Division of Internal Medicine, S. Luigi Hospital, Orbassano
- Gianpietro Semenzato
- Hematology University Division, Padova
- Francesco Lanza
- Hematology Unit, Cremona
- Tommasina Perrone
- Hematology University Division, Bari
- Francesco Angrilli
- Hematology Division, Pescara
- Atto Billio
- Hematology Division, Bolzano
- Angela Gueli
- Onco-Hematology Division, IEO, European Institute of Oncology IRCCS, Milano
- Barbara Mantoan
- Hematology University Division, Città della Salute Hospital, Torino
- Alessandro Rambaldi
- Hematology Division, Papa Giovanni XXIII Hospital, Bergamo;Department of Oncology and Onco-Hematology, University of Milan, Milano
- Alessandro Massimo Gianni
- Onco-Hematology Division, IEO, European Institute of Oncology IRCCS, Milano
- Paolo Corradini
- University Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;Department of Oncology and Onco-Hematology, University of Milan, Milano
- Roberto Passera
- Nuclear Medicine Division, Città della Salute Hospital, Torino
- Marco Ladetto
- SC Ematologia AO SS Antonio e Biagio e Cesare Arrigo, Alessandria
- Corrado Tarella
- Onco-Hematology Division, IEO, European Institute of Oncology IRCCS, Milano;Department of Health Sciences, University of Milan, Milano, Italy
- DOI
- https://doi.org/10.3324/haematol.2018.209932
- Journal volume & issue
-
Vol. 104,
no. 11
Abstract
A prospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (R-HDS) versus conventional chemotherapy with rituximab (CHOP-R) as first-line therapy in 134 high-risk follicular lymphoma patients aged
